ArticlePloS one2020
Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multidisciplinary meeting review in nonsmall cell lung cancer: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Multidisciplinary Team Care for Early-Stage Lung Cancer in Low- and Middle-Income Countries and Emerging Economies: Current Position and Call for Action.Thoracic cancer · 2026Review
- [Current Status of Multidisciplinary Team Consultation for Lung Cancer and Prospects under the Empowerment of Medical Large Models].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Association between treatment decisions and survival outcomes in lung cancer patients under a multidisciplinary team model: the impact of MDT-recommended treatment plans on treatment completion rates, survival time, and treatment conversion.Frontiers in oncology · 2026Article
- Advancing Lung Cancer Care in Bulgaria: A Successful Implementation of Value-Based Healthcarе.Journal of patient experience · 2026Article
- A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Review
- The Impact of Multidisciplinary Team Meetings on the Survival of Stage IV NSCLC Patients.Cancer medicine · 2025Article
- Multidisciplinary tumour boards and surgical intervention improve overall survival in patients with Stage III non-small-cell lung cancer: a retrospective cohort study.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States.Advances in therapy · 2025Article
- Prevalence ofLung Cancer (Auckland, N.Z.) · 2025Article
- Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review.Cancer metastasis reviews · 2024Review
- The Impact of a Multidisciplinary Team Conference on Non-Small Cell Lung Cancer Care: Time Barriers and Long-Term Outcomes.Journal of clinical medicine · 2024Article
- Prognostic factors for recurrence-free survival in resected pathologic N2-stage III non-small cell lung cancer treated with upfront surgery.Journal of the Chinese Medical Association : JCMA · 2024Article
- The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Does Multidisciplinary Team Management Improve Clinical Outcomes in NSCLC? A Systematic Review With Meta-Analysis.JTO clinical and research reports · 2023Review
- Multidisciplinary team discussion: the emerging gold standard for management of cardiopulmonary complications of connective tissue disease.Internal medicine journal · 2023Review
- Patient selection for minimally-invasive resection of complex, central lung tumors: taking account of the surgeon's eyeball test.Journal of thoracic disease · 2023Article
- Real-World Perspectives From Surgeons and Oncologists on Resectability Definition and Multidisciplinary Team Discussion of Stage III NSCLC in People's Republic of China, Hong Kong, and Macau: A Physician Survey.JTO clinical and research reports · 2022Article
- Preliminary evaluation of a new initiative to centralize colorectal cancer care during the COVID-19 epidemic in Shanghai, China: a retrospective study.Annals of translational medicine · 2022Article
- Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer.Pulmonary therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment for stage III non-small cell lung cancer (NSCLC) often involves multi-modality treatment. This retrospective study aimed to evaluate whether multidisciplinary team (MDT) discussion results in better patient survival. MATERIALS AND
methodsMDT discussion was optional before February 2016 and was actively encouraged by the MDT committee beginning February 2016. We reviewed the medical charts and computer records of patients with stage III NSCLC between January 2013 and December 2018.
resultsA total of 515 patients were included. The median survival of all the patients was 33.9 months (M). The median survival of patients who were treated after MDT discussion was 41.2 M and that of patients treated without MDT discussion was 25.7 M (p = 0.018). The median survival of patients treated before February 2016 was 25.7 M and that of patients treated after February 2016 was 33.9 M (p = 0.003). The median survival of patients with stage IIIA tumors and those with stage IIIB tumors was 39.4 M and 25.7 M, respectively (p = 0.141). Multivariate analysis showed that MDT or not (p<0.001), T staging (p = 0.009), performance status (p<0.001), and surgery (p = 0.016) to be significant prognostic factors.
conclusionThe results of the study show that MDT discussion results in survival benefit in patients with stage III NSCLC. The MDT discussion, performance status, and if surgery was performed were independent prognostic factors for patients with stage III NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.